Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Next Previous
X
Search
Trial Profile

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms ProCID
  • Sponsors Octapharma

    • Most Recent Events

    • 28 Jun 2023 Results assessing safety published in the Drug Safety.
    • 12 Feb 2021 Primary endpoint has been met. (Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score), according to a Pfizer media release.
    • 12 Feb 2021 Results published in the Pfizer Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top